Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Schrödinger, the US-based life sciences platform developer backed by internet and technology conglomerate Alphabet and pharmaceutical firm Wuxi AppTec, closed its initial public offering at more than $232m yesterday. The company floated last week, issuing nearly 11.9 million shares on the Nasdaq Global Market priced at $17.00 each. Its shares closed at $28.64 on their…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.